User:Evathedutch/sandbox

Spruce Biosciences, Inc. (Nasdaq: SPRB), is a biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The Company, which is based in San Fransisco, California is developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH and for females suffering from polycystic ovary syndrome (PCOS). Samir Gharib is the current President and CFO.

Spruce Biosciences's poster presentation was accepted for the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL. In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.